GB201908729D0 - RNA construct - Google Patents

RNA construct

Info

Publication number
GB201908729D0
GB201908729D0 GBGB1908729.5A GB201908729A GB201908729D0 GB 201908729 D0 GB201908729 D0 GB 201908729D0 GB 201908729 A GB201908729 A GB 201908729A GB 201908729 D0 GB201908729 D0 GB 201908729D0
Authority
GB
United Kingdom
Prior art keywords
rna construct
rna
construct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1908729.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Imperial College Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial College Innovations Ltd filed Critical Imperial College Innovations Ltd
Priority to GBGB1908729.5A priority Critical patent/GB201908729D0/en
Publication of GB201908729D0 publication Critical patent/GB201908729D0/en
Priority to KR1020227001607A priority patent/KR20220038669A/ko
Priority to US17/617,831 priority patent/US12569548B2/en
Priority to CN202080045184.7A priority patent/CN114402078B/zh
Priority to PCT/GB2020/051465 priority patent/WO2020254804A1/en
Priority to AU2020296337A priority patent/AU2020296337B2/en
Priority to MX2021015753A priority patent/MX2021015753A/es
Priority to JP2021575438A priority patent/JP2022537562A/ja
Priority to CA3143117A priority patent/CA3143117A1/en
Priority to BR112021024786A priority patent/BR112021024786A2/pt
Priority to EP20734803.8A priority patent/EP3987042A1/en
Priority to IL288956A priority patent/IL288956A/en
Priority to JP2025081437A priority patent/JP2025118871A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB1908729.5A 2019-06-18 2019-06-18 RNA construct Ceased GB201908729D0 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
GBGB1908729.5A GB201908729D0 (en) 2019-06-18 2019-06-18 RNA construct
EP20734803.8A EP3987042A1 (en) 2019-06-18 2020-06-18 Rna construct
MX2021015753A MX2021015753A (es) 2019-06-18 2020-06-18 Constructo de arn.
US17/617,831 US12569548B2 (en) 2019-06-18 2020-06-18 RNA construct
CN202080045184.7A CN114402078B (zh) 2019-06-18 2020-06-18 Rna构建体
PCT/GB2020/051465 WO2020254804A1 (en) 2019-06-18 2020-06-18 Rna construct
AU2020296337A AU2020296337B2 (en) 2019-06-18 2020-06-18 RNA construct
KR1020227001607A KR20220038669A (ko) 2019-06-18 2020-06-18 Rna 구조체
JP2021575438A JP2022537562A (ja) 2019-06-18 2020-06-18 Ｒｎａ構築物
CA3143117A CA3143117A1 (en) 2019-06-18 2020-06-18 Rna construct
BR112021024786A BR112021024786A2 (pt) 2019-06-18 2020-06-18 Construção de rna, sequência de ácido nucleico, cassete de expressão, vetor recombinante, composição farmacêutica, método para preparar a construção de rna, vacina, método para modificar uma célula ex vivo ou in vitro e célula modificada
IL288956A IL288956A (en) 2019-06-18 2021-12-13 RN" A building
JP2025081437A JP2025118871A (ja) 2019-06-18 2025-05-14 Ｒｎａ構築物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1908729.5A GB201908729D0 (en) 2019-06-18 2019-06-18 RNA construct

Publications (1)

Publication Number Publication Date
GB201908729D0 true GB201908729D0 (en) 2019-07-31

Family

ID=67432317

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1908729.5A Ceased GB201908729D0 (en) 2019-06-18 2019-06-18 RNA construct

Country Status (12)

Country Link
US (1) US12569548B2 (https=)
EP (1) EP3987042A1 (https=)
JP (2) JP2022537562A (https=)
KR (1) KR20220038669A (https=)
CN (1) CN114402078B (https=)
AU (1) AU2020296337B2 (https=)
BR (1) BR112021024786A2 (https=)
CA (1) CA3143117A1 (https=)
GB (1) GB201908729D0 (https=)
IL (1) IL288956A (https=)
MX (1) MX2021015753A (https=)
WO (1) WO2020254804A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110168093B (zh) * 2017-09-12 2023-08-15 中科蓝华(广州)生物医药技术有限公司 一种转染细胞内寄生虫的试剂盒及其应用
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
US20210369759A1 (en) * 2020-01-29 2021-12-02 Helix Nanotechnologies, Inc. METHODS AND COMPOSITIONS FOR NUCLEIC ACID EXPRESSION INVOLVING INHIBITION of NF-kB PATHWAYS AND/OR IRF PATHWAYS
AU2021236068A1 (en) 2020-03-09 2022-10-06 Arcturus Therapeutics, Inc. Compositions and methods for inducing immune responses
KR20220156933A (ko) 2020-03-23 2022-11-28 에이치디티 바이오 코포레이션 Rna의 전달을 위한 조성물 및 방법
EP4196128A4 (en) 2020-08-14 2024-06-12 Arcturus Therapeutics, Inc. METHOD FOR FREEZE DILIZATION OF LIPID NANOPARTICLES
GB202020061D0 (en) * 2020-12-17 2021-02-03 Imp College Innovations Ltd RNA construct
EP4267593A2 (en) 2020-12-23 2023-11-01 GlaxoSmithKline Biologicals SA Self-amplifying messenger rna
US20240240201A1 (en) 2021-05-04 2024-07-18 Mogrify Limited Cell conversion
CN113249408B (zh) * 2021-06-23 2021-11-02 深圳湾实验室 一种靶向激活体液免疫和细胞免疫的核酸疫苗载体构建及应用
JP2024535354A (ja) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション がん治療組成物およびその使用
CA3232719A1 (en) 2021-09-22 2023-03-30 Steven Gregory REED Sars-cov-2 rna vaccine compositions and methods of use
WO2023048760A1 (en) 2021-09-22 2023-03-30 Hdt Bio Corp. Rna vaccines against infectious diseases
EP4404919A4 (en) 2021-09-22 2025-08-20 Hdt Bio Corp DRIED NANOPARTICLE COMPOSITIONS
CN118715325A (zh) * 2021-12-17 2024-09-27 帝国理工创新有限公司 Rna构建体
GB202203060D0 (en) 2022-03-04 2022-04-20 Imperial College Innovations Ltd RNA molecule
CN119563028A (zh) * 2022-05-12 2025-03-04 尚威天成信使核糖核酸治疗公司 具有分泌抗原和免疫调节物的合成自扩增mRNA分子
CN115820696A (zh) * 2022-07-28 2023-03-21 怡道生物科技(苏州)有限公司 治疗性多价HPV mRNA疫苗及其制备方法
KR20240133629A (ko) * 2023-02-27 2024-09-04 주식회사 마이크로유니 자가 증폭 rna 컨스트럭트 및 이의 용도
WO2025008641A2 (en) 2023-07-06 2025-01-09 Imperial College Innovations Limited Rna molecule
CN121586776A (zh) * 2023-07-19 2026-02-27 上海复诺健生物科技有限公司 自扩增核酸分子及其应用
GB202313445D0 (en) 2023-09-04 2023-10-18 Imperial College Innovations Ltd Rna molecule
WO2025217136A2 (en) * 2024-04-08 2025-10-16 Amplitude Therapeutics, Inc. Trans-amplifying rnas encoding immunomodulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110117124A1 (en) 2007-08-31 2011-05-19 Sadoff Jerald C Enhancement of transgene expression from viral-based vaccine vectors by expression of suppressors of the type i interferon response
US7608256B2 (en) 2007-09-12 2009-10-27 Aeras Global Tb Vaccine Foundation Methods to increase transgene expression from bacterial-based delivery systems by co-expressing suppressors of the eukaryotic type I interferon response
US20140037680A1 (en) * 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
TR201809547T4 (tr) * 2012-11-09 2018-07-23 Biontech Rna Pharmaceuticals Gmbh Hücresel RNA ifadesine yönelik yöntem.
GB2592821B (en) * 2015-07-31 2022-01-12 Univ Minnesota Modified cells and methods of therapy
CA3045650A1 (en) * 2016-12-05 2018-06-14 Janssen Pharmaceuticals, Inc. Compositions and methods for enhancing gene expression

Also Published As

Publication number Publication date
KR20220038669A (ko) 2022-03-29
CN114402078B (zh) 2025-11-14
US12569548B2 (en) 2026-03-10
MX2021015753A (es) 2022-04-12
WO2020254804A1 (en) 2020-12-24
BR112021024786A2 (pt) 2022-02-22
AU2020296337A1 (en) 2021-12-23
EP3987042A1 (en) 2022-04-27
US20220265807A1 (en) 2022-08-25
JP2025118871A (ja) 2025-08-13
IL288956A (en) 2022-02-01
CN114402078A (zh) 2022-04-26
AU2020296337B2 (en) 2025-12-18
CA3143117A1 (en) 2020-12-24
JP2022537562A (ja) 2022-08-26

Similar Documents

Publication Publication Date Title
IL288956A (en) RN" A building
IL274442A (en) RNA sequence alignment
GB202018087D0 (en) No details
GB202017837D0 (en) No details
GB202018573D0 (en) No details
GB202013426D0 (en) No Details
GB202009212D0 (en) No details
CA189498S (en) Showerbase
IL277921A (en) RNA new small operators
GB201901778D0 (en) Aladin
GB202020126D0 (en) No details
GB201907392D0 (en) Proof-of-work
GB201913898D0 (en) Nucleic acid construct
GB202020061D0 (en) RNA construct
GB202015405D0 (en) No details
GB202020063D0 (en) RNA construct
GB202019395D0 (en) No details
GB202014354D0 (en) No details
GB202018699D0 (en) No details
GB202006205D0 (en) No details
GB201911522D0 (en) Genetic construct
GB202018214D0 (en) No details
GB202020064D0 (en) RNA construct
GB202103183D0 (en) No details
GB201917045D0 (en) Genetic construct

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)